Newest OncoKB updates: October 24, 2023

[Contact OncoKB]

Dear OncoKB user,

Here are the latest OncoKB updates:

October 24, 2023Data version: v4.10

• Updated therapeutic implications - Changed level of evidence

  Gene	Mutation	Cancer Type	Drug(s)	Previous Level	Current Level	Reason
  KRAS	G12C	Colorectal Cancer	Drug(s) currently in OncoKB™: Adagrasib + Cetuximab (Level 3A) Drug(s) added to OncoKB™: Adagrasib + Panitumumab; Sotorasib + Cetuximab; Sotorasib + Panitumumab	3A	2	Inclusion in Colon Cancer NCCN guidelines v3.2023 and in Rectal Cancer NCCN guidelines v5.2023; PMID: 36546659; Abstract: Kuboki et al. Abstract# 45MO, ESMO 2022.

• Updated therapeutic implications - Addition of therapies for variants with a level of evidence

  Gene	Mutation	Cancer Type	Current Level of Evidence	Drug(s) currently in OncoKB™	Drug(s) added to OncoKB™	Evidence
  BRAF	V600E	Non-Small Cell Lung Cancer	1	Dabrafenib + Trametinib (Level 1)	Encorafenib + Binimetinib (Level 1)	FDA-approval of Encorafenib + Binimetinib for BRAF V600E NSCLC; PMID: 37270692

• Addition of 6 new genes:
  EPHB4ETS1FANCEFANCFFANCGMYB

--

The OncoKB Team